within Pharmacolibrary.Drugs.ATC.J;

model J01DI54
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 0.05,
    adminDuration  = 600,
    adminMass      = 1.0,
    adminCount     = 1,
    Vd             = 0.0135,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Ceftolozane and tazobactam is a combination of a cephalosporin antibiotic (ceftolozane) and a β-lactamase inhibitor (tazobactam). It is used for the treatment of complicated intra-abdominal infections and complicated urinary tract infections, including pyelonephritis. The combination is approved for clinical use and has activity against Gram-negative pathogens, including multidrug-resistant Pseudomonas aeruginosa.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters obtained in healthy adult subjects, both male and female, age range approximately 18–50 years, following intravenous infusion.</p><h4>References</h4><ol><li><p>van Duin, D, &amp; Bonomo, RA (2016). Ceftazidime/Avibactam and Ceftolozane/Tazobactam: Second-generation β-Lactam/β-Lactamase Inhibitor Combinations. <i>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</i> 63(2) 234–241. DOI:<a href=&quot;https://doi.org/10.1093/cid/ciw243&quot;>10.1093/cid/ciw243</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/27098166/&quot;>https://pubmed.ncbi.nlm.nih.gov/27098166</a></p></li><li><p>Nicolau, DP, et al., &amp; Rizk, ML (2021). Pharmacokinetics and Pharmacodynamics of Ceftolozane/Tazobactam in Critically Ill Patients With Augmented Renal Clearance. <i>International journal of antimicrobial agents</i> 57(4) 106299–None. DOI:<a href=&quot;https://doi.org/10.1016/j.ijantimicag.2021.106299&quot;>10.1016/j.ijantimicag.2021.106299</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33567333/&quot;>https://pubmed.ncbi.nlm.nih.gov/33567333</a></p></li><li><p>Al Jalali, V, et al., &amp; Zeitlinger, M (2021). Plasma and soft tissue pharmacokinetics of ceftolozane/tazobactam in healthy volunteers after single and multiple intravenous infusion: a microdialysis study. <i>The Journal of antimicrobial chemotherapy</i> 76(9) 2342–2351. DOI:<a href=&quot;https://doi.org/10.1093/jac/dkab166&quot;>10.1093/jac/dkab166</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/34050650/&quot;>https://pubmed.ncbi.nlm.nih.gov/34050650</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end J01DI54;
